Spending on disease-modifying MS therapies doubled in 7 years

Researchers have determined that, in the USA, spending on disease-modifying multiple sclerosis (MS) drug therapies more than doubled between 2011 and 2017, despite the market introduction of a generic version of one the most commonly prescribed drugs. Researchers from Oregon State University (OR, USA) have analyzed data on Medicaid drug utilization across the USA and determined that spending on disease-modifying multiple sclerosis (MS) drug therapies almost tripled between 2011 and 2017, despite the market introduction of a generic version of one the most commonly prescribed drugs. Disease-modifying therapies, such as glatiramer acetate — the most commonly prescribed disease-modifying drug for...